Allogeneic hematopoietic stem cell transplantation (allo-HSCT) following myeloablative conditioning represents the treatment of choice for patients with chemotherapy-resistant leukemia. We describe a 49-year-old man with advanced, refractory acute myelogenous leukemia (AML) that was treated successfully by allogeneic bone marrow transplantation from a sibling donor with HLA mismatched at 1 locus. However, the patient developed a quiescent form of chronic graft-versus-host disease (GVHD) 7 years after transplantation, requiring long-term immunosuppressive therapy. AML relapse was documented 11 years after transplantation. Subsequently, Epstein-Barr virus (EBV)-associated posttransplantation lymphoprolif-erative disorder (PTLD) was also diagnosed. Immune reconstitution after allo-HSCT might have been impaired by the persistent chronic GVHD and the prolonged administration of immunosuppressive agents. As a result, immune surveillance against remaining quiescent leukemic cells as well as viral infection may have been defective, leading to the relapse of leukemia and EBV-associated PTLD.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Estey EH. Treatment of relapsed and refractory acute myeloge- nous leukemia. Leukemia. 2000;14:476–479.
Stone RM, O’Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program). 2004:98-117.
Song KW, Lipton J. Is it appropriate to offer allogeneic hemato- poietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? Bone Marrow Transplant. 2005;36:183–191.
Michallet M, Thomas X,Vernant JP, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Française de Gréffé de Moelle (SFGM). Bone Marrow Transplant. 2000;26:1157–1163.
Gale RP, Horowitz MM, Rees JK, et al. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia. 1996;10:13–19.
Lin J, Markowitz GS, Nicolaides M, et al. Membranous glomeru- lopathy associated with graft-versus-host disease following allo- geneic stem cell transplantation: report of 2 cases and review of the literature. Am J Nephrol. 2001;21:351–356.
Rossi L, Cardarelli F, Vampa ML, Buzio C, Olivetti G. Membranous glomerulonephritis after haematopoietic cell transplantation for multiple myeloma. Nephron. 2001;88:260–263.
Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia. 1995;9:10–14.
Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313:765–771.
Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320:197–204.
Anasetti C, Beatty PG, Storb R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol. 1990;29:79–91.
Kanda Y, Chiba S, Hirai H, et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identi- cal siblings over the last decade (1991-2000). Blood. 2003;102: 1541–1547.
Bertz H, Kunzman R, Bunjes D, Finke J. Successful adoptive immunotherapy for relapse of AML 9 years after T-cell-depleted BMT. Br J Haematol. 1998;103:563–564.
Yong AS, Goldman JM. Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;23:827–828.
Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood. 1988;71:1234–1243.
Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208–2216.
Meijer E, Dekker AW, Weersink AJ, Rozenberg-Arska M, Verdonck LF. Prevention and treatment of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of bone marrow and solid organ transplants. Br J Haematol. 2002; 119:596–607.
Bollard CM, Savoldo B, Rooney CM, Heslop HE. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol. 2003;110:139–148.
About this article
Cite this article
Kikushige, Y., Takase, K., Miyamoto, T. et al. Late Relapse of Acute Myelogenous Leukemia Followed by Epstein-Barr Virus—Associated Lymphoproliferative Disease 11 Years After Allogeneic Bone Marrow Transplantation. Int J Hematol 84, 441–444 (2006). https://doi.org/10.1532/IJH97.06113